Last reviewed · How we verify
Bepotastine Besilate Nasal Spray 3% Twice a day
Bepotastine Besilate Nasal Spray 3% Twice a day is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 2 development.
At a glance
| Generic name | Bepotastine Besilate Nasal Spray 3% Twice a day |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bepotastine Besilate Nasal Spray 3% Twice a day CI brief — competitive landscape report
- Bepotastine Besilate Nasal Spray 3% Twice a day updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about Bepotastine Besilate Nasal Spray 3% Twice a day
What is Bepotastine Besilate Nasal Spray 3% Twice a day?
Bepotastine Besilate Nasal Spray 3% Twice a day is a Small molecule drug developed by Bausch & Lomb Incorporated.
Who makes Bepotastine Besilate Nasal Spray 3% Twice a day?
Bepotastine Besilate Nasal Spray 3% Twice a day is developed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).
What development phase is Bepotastine Besilate Nasal Spray 3% Twice a day in?
Bepotastine Besilate Nasal Spray 3% Twice a day is in Phase 2.